Doctor Knowledge Of Cancer Treatment Options, Costs Key To Advising On Proper Medical Care
Main Category: Cancer / OncologyAlso Included In: Primary Care / General Practice
Article Date: 03 Jul 2008 - 2:00 PDT
The growing number of cancer treatment options and their widely varying costs suggest an increased need for oncologists to understand economic issues in cancer care and be able to discuss these issue with their patients, according to a study by researchers at the University of Texas M.D. Anderson Cancer Center and RTI International.
The study, published in the July/August issue of CA: A Cancer Journal for Clinicians, found that rising health care costs as well as health care budget constraints have made it necessary for clinicians to be aware of the relative costs and benefits of new interventions used in cancer screening, diagnosis, treatment and support services for patients.
"A doctor's job is to provide the best care for his or her patients," said Michael Halpern, M.D., Ph.D., a senior researcher at RTI International and the study's co-author. "Unless clinicians, other cancer health care providers, and cancer researchers are active participants in discussions regarding the costs and benefits of new interventions, others will make these cost-effectiveness conclusions."
Many new cancer interventions may help specific populations but also result in much higher costs such as magnetic resonance imaging screening for breast cancer, which at $1,000 per image is ten times the cost of screening mammography.
Other examples include $48,000 per patient per year for the use of intensity-modulated radiation therapy to treat prostate cancer, $50,000 per patient per year for trastuzumab (Herceptin) in the treatment of HER- 2 positive breast cancer, and more than $8,000 for a six-day course of palifermin (Kepivance) to treat oral mucositis.
"In our country's medical system, patients are often required to pay for a proportion of their medical care," said Ya-Chen Tina Shih, Ph.D., an associate professor at the University of Texas M.D. Anderson Cancer Center and the report's lead author. "As the growth of medical care costs outpaces general inflation, patients are spending an increasing proportion of their family incomes on medical care. In addition, limited health care funds require medical care to be prioritized to determine the most reasonable use of those funds. These factors make it increasingly important for clinicians to consider the economic aspect of cancer treatments so they are providing their patients with information on the costs and benefits of different treatment options."
The report provides a review of the methods used for economic analyses to help clinicians understand how economic evaluations of cancer interventions are performed so they are better able to use, and critique, these evaluations.
About RTI International
RTI International is one of the world's leading research institutes, dedicated to improving the human condition by turning knowledge into practice. Our staff of more than 2,600 provides research and technical services to governments and businesses worldwide in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy, and the environment. RTI also employs about 1,200 term employees who support projects in more than 40 countries. For more information, visit http://www.rti.org.
RTI International
3040 Cornwallis Rd.
Research Triangle Park, NC 27709-2194
United States
http://www.rti.org
Visit our cancer / oncology section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/113751.php>
APA
http://www.medicalnewstoday.com/releases/113751.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
The Economic Issues In Cancer Care
posted by Gregory D. Pawelski on 5 Jul 2008 at 10:26 pmIt amazes me not only that some private insurance carriers don't like to pay for oncologic in vitro chemoresponse assays but that they don't emphatically mandate it as a requirement for obtaining chemotherapy reimbursement against ill-directed treatments. Evidence in support of these tests is more than sufficient to justify them.
Profit, as we have seen, is a powerful motivating force. Among the private payors, at least, the profit motive is entirely consistent with the goal of the tests, which is to identify efficacious therapies irrespective of drug mark-up rates.
Everyone is scared to death - and rightly so - at what is going to happen to the healthcare economic system with increasingly expensive new drugs that benefit only a small percentage of patients who receive them. Hence the headlong rush to develop companion diagnostic tests to identify molecular predisposing mechanisms whose presence still does not guarantee that a drug will be effective for an individual patient.
The pressure, in fact, is so great that these molecular companion diagnostics they've approved often have been mostly or totally ineffective at identifying clinical responders (durable and otherwise) to the various therapies. Nor can they, for any patient or even large group of patients, discriminate the potential for clinical activity among different agents of the same class.
The FDA could benefit too, as they find themselves under increasing pressure to allow new drugs into marketplace while at the same time protecting the safety of potential recipients of those drugs as well as the financial interests of those who will have to pay for them.
I think that in both of these areas - private insurance carriers and the FDA - there is a very real opportunity to make a substantial impact and contribution, an interest in saving the healthcare system perhaps billions of dollars a year by ensuring that expensive treatments are used appropriately.
Committee chairpersons, committee members and persons in congress who may have personal interests not only in discovering new cancer treatments - everybody wants that - but also, in the "here and now," using currently-available cell culture assay technologies to improve the effectiveness of existing drugs and save lives today by administering the right drug to the right patient at the right time.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




